(Total Views: 321)
Posted On: 08/29/2022 9:23:19 AM
Post# of 1418
![Avatar](https://investorshangout.com/images/ProfileImages/no_avatar_available.jpg)
Todos Medical Expands COVID Onsite School Sample Collection to Include MonkeyPox Testing
New York, NY, and Tel Aviv, ISRAEL, Aug. 29, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- Todos Medical, Ltd. (OTCQB: TOMDF), a comprehensive medical diagnostics and related solutions company, today announced that its Atlanta-area CLIA/CAP-certified clinical laboratory, Provista Diagnostics, Inc., is expanding its onsite school sample collection programs for COVID-19 PCR testing to include MonkeyPox testing. Provista is able to test for both COVID-19 and MonkeyPox from the same saliva sample. The expansion of onsite sample collection support for schools to include MonkeyPox is designed for a situation where a school has a confirmed MonkeyPox case, whether from staff or students, and there is a desire from school administrators to screen staff and students entering the school in order to contain potential MonkeyPox outbreaks. In these situations, it is highly recommended that schools simultaneously test for COVID-19 in order to minimize the potential that students could be simultaneously infected with COVID and MonkeyPox, as has recently been reported can occur. The service is initially available in select Georgia and New Jersey districts where Provista already has established capabilities. The Company plans to expand the jurisdictions in which this service is available through sample collection partnerships in the near future.
“We have been moving extremely fast to get ahead of the curve in MonkeyPox testing, and providing access to screening programs is the obvious next step to help facilitate the containment of outbreaks in school settings,” said Gerald E. Commissiong, President & CEO of Todos Medical. “While the federal government’s response to the MonkeyPox public health emergency continues to evolve, we are focused on the practical implications of what this could mean for real people in our communities. COVID-19 remains a major threat to health, especially in children who appear to be at higher risk of developing Long COVID (1 in 4 for children vs. 1 in 5 for adults), and as such it is prudent to conduct screening for COVID-19 alongside any MonkeyPox outbreak. This has the dual benefit of pinpointing individuals who may be at greatest risk of poor outcomes due to dual infections, and has the benefit of likely lowering COVID-19 transmission in schools by identifying asymptomatic cases of individuals who were previously spreading SARS-CoV-2. Given that the expectation is weekly screening for MonkeyPox testing for 2-3 weeks after a confirmed case is identified in a school setting, the simultaneous benefit of substantially lowering within school transmission has obvious long-term benefits for the health of the school population. We are proud to be able to bring this innovative solution to market so rapidly to help protect our communities
https://investor.todosmedical.com/news-events...collection
New York, NY, and Tel Aviv, ISRAEL, Aug. 29, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- Todos Medical, Ltd. (OTCQB: TOMDF), a comprehensive medical diagnostics and related solutions company, today announced that its Atlanta-area CLIA/CAP-certified clinical laboratory, Provista Diagnostics, Inc., is expanding its onsite school sample collection programs for COVID-19 PCR testing to include MonkeyPox testing. Provista is able to test for both COVID-19 and MonkeyPox from the same saliva sample. The expansion of onsite sample collection support for schools to include MonkeyPox is designed for a situation where a school has a confirmed MonkeyPox case, whether from staff or students, and there is a desire from school administrators to screen staff and students entering the school in order to contain potential MonkeyPox outbreaks. In these situations, it is highly recommended that schools simultaneously test for COVID-19 in order to minimize the potential that students could be simultaneously infected with COVID and MonkeyPox, as has recently been reported can occur. The service is initially available in select Georgia and New Jersey districts where Provista already has established capabilities. The Company plans to expand the jurisdictions in which this service is available through sample collection partnerships in the near future.
“We have been moving extremely fast to get ahead of the curve in MonkeyPox testing, and providing access to screening programs is the obvious next step to help facilitate the containment of outbreaks in school settings,” said Gerald E. Commissiong, President & CEO of Todos Medical. “While the federal government’s response to the MonkeyPox public health emergency continues to evolve, we are focused on the practical implications of what this could mean for real people in our communities. COVID-19 remains a major threat to health, especially in children who appear to be at higher risk of developing Long COVID (1 in 4 for children vs. 1 in 5 for adults), and as such it is prudent to conduct screening for COVID-19 alongside any MonkeyPox outbreak. This has the dual benefit of pinpointing individuals who may be at greatest risk of poor outcomes due to dual infections, and has the benefit of likely lowering COVID-19 transmission in schools by identifying asymptomatic cases of individuals who were previously spreading SARS-CoV-2. Given that the expectation is weekly screening for MonkeyPox testing for 2-3 weeks after a confirmed case is identified in a school setting, the simultaneous benefit of substantially lowering within school transmission has obvious long-term benefits for the health of the school population. We are proud to be able to bring this innovative solution to market so rapidly to help protect our communities
https://investor.todosmedical.com/news-events...collection
![](/m/images/thumb-up.png)
![](/m/images/thumb-down.png)